Pralsetinib launch date in China

In March 2021, Pralsetinib was approved by the National Medical Products Administration and was launched in China under the trade name Pujihua. Platinib is a receptor tyrosine kinase RET inhibitor that can selectively inhibit RET kinase activity, dose-dependently inhibit the phosphorylation of RET and its downstream molecules, and effectively inhibit the proliferation of cells expressing RET (wild type and multiple mutants). The indication for listing in China is the treatment of adult patients with transfection rearrangement (RET) gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-containing chemotherapy, providing a new treatment option for adult patients.